CERAMENT™|G Featured In Documentary 'The Orthopaedic Revolution: Treating Osteomyelitis'

LUND, Sweden, Aug. 5, 2014 /CNW/ -- BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that CERAMENT™|G is a prominent feature in a new documentary,  'The Orthopaedic Revolution:  Treating Osteomyelitis', which recently aired on the National Health Channel. The documentary features Martin McNally, Lead Surgeon and Andrew Woodhouse, Lead Infectious Disease Consultant at the Bone Infection Unit of the Nuffield Orthopaedic Centre in Oxford, and explores a multidisciplinary approach to patient care, highlighting the risk of antibiotic resistance and the impact of new innovations such as the local delivery of antibiotics directly into the bone.  The program further discusses clinical experience with CERAMENT™|G, the first injectable antibiotic eluting bone substitute indicated to promote and protect bone healing being jeopardized by infection.

Osteomyelitis (bone infection) is a $1.7 billion market where prolonged, long-term antibiotic therapy, repeated unsuccessful surgical interventions and the threat of amputation are the current standard of care. An increase in prosthetic infections, diabetic ulcers, war injuries, sports injuries, and antibiotic resistance contribute to rising rates of osteomyelitis and increased costs to the NHS.

The 15-minute program features interviews with leading experts in the field of orthopedics and bone infection, and provides a first-hand account by patient Arthur Edinburgh, chronicling the devastating impact of osteomyelitis and his remarkable recovery after treatment at the Bone Infection Unit.

 "This documentary will play a formative role in helping health providers better understand the management of bone infections, the impact of antibiotic resistance and the potential role that CERAMENT™|G can play in respect of this growing threat," said Lloyd Diamond, CEO of BONESUPPORT.  "As the first antibiotic eluting bone substitute, CERAMENT™|G has the potential to impact the surgical strategy by providing a more effective delivery of antibiotics, thereby reducing treatment time, minimizing surgical intervention and lowering healthcare costs."

The documentary is available for viewing at:  http://www.nationalhealthchannel.tv/videos/the-orthopaedic-revolution-treating-osteomyelitis/

About National Health Service (NHS)

The NHS was founded in 1948 and is among the world's largest public funded health services.  The NHS in England provides free healthcare to a population of 53 million and employs more than 1.35 million people.  Funding for the NHS comes directly from taxation and is granted to the Department of Health by Parliament.  

About the Oxford Bone Infection Unit

The Oxford Unit is a purpose built 26-bed in-patient facility, within the Oxford University Hospitals NHS Trust, providing multi-disciplinary care to patients with all aspects of infection in the bones and joints.  The team has a major interest in infected joint replacements and infection after fractures and injuries.  Referrals can be made from all over the UK by GPs or surgeons via e-mail at: boneinfection.noc@nhs.net or via the website at www.ouh.nhs.uk/boneinfection.

About BONESUPPORT

BONESUPPORT is an emerging leader of injectable bone graft substitutes for orthopedic trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENT™ is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENT's unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENT™|G is the first CE-marked injectable antibiotic eluting ceramic bone graft substitute.  CERAMENT™|G is indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections) in CE marked countries.  CERAMENT™|G is not available in the United States.

CERAMENT™ is a fully developed product platform that is commercially available in the U.S. and Europe and is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT spans more than eleven years. Over forty-five pre-clinical, clinical and animal studies have been conducted and close to 9,000 patients have been treated with CERAMENT.  The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT please visit www.bonesupport.com.

Press Inquiries:
Offer Nonhoff
Chief Financial Officer
Offer.Nonhoff@bonesupport.com
Phone +46 46 286 53 60

PR 0368-01 en

SOURCE BONESUPPORT